Cerus Corp represents a commitment to ensuring the safety of the global blood supply. With a strong corporate philosophy focused on innovation and collaboration, Cerus Corp strives to provide innovative solutions to enhance transfusion medicine. The company's values revolve around patient-centricity, quality, and integrity, ensuring the highest standards in product development and commercialization. By leveraging their cutting-edge technologies like the INTERCEPT Blood System, Cerus Corp aims to prevent the risk of transfusion-transmitted infections and improve patient outcomes. Through their dedication to safety and pioneering advancements, Cerus Corp continues to play a vital role in protecting lives through safer blood transfusions.

Cerus Corp, a leading healthcare company, primarily operates in various countries and regions worldwide. With a global presence, the company's main operations can be found in North America, including the United States and Canada, where it is headquartered. Furthermore, Cerus Corp has an established footprint in Europe, particularly in countries like Germany, France, and the United Kingdom. Additionally, the company extends its reach to the Asia-Pacific region, encompassing countries such as Japan and Australia. Cerus Corp's international presence showcases its commitment to providing innovative solutions and services in transfusion medicine and blood safety on a global scale.

Cerus Corp has achieved several significant milestones. The company's Intercept Blood System has received regulatory approvals in key markets, including the United States and Europe. This innovative technology has revolutionized blood safety by reducing the risk of transfusion-transmitted infections. Cerus Corp has also established successful collaborations with leading organizations, securing partnerships and licensing agreements to expand its market presence. Moreover, the company has conducted extensive clinical trials, demonstrating the safety and efficacy of its products. With a strong commitment to advancing medical advancements, Cerus Corp continues to make remarkable strides in improving the safety and availability of blood products worldwide.

Cerus Corp is a medical device company founded in 1991. It specializes in developing and commercializing blood transfusion safety systems. With its flagship product, the INTERCEPT Blood System, Cerus Corp is dedicated to preventing the transmission of infectious diseases through blood transfusions. The innovative technology of the INTERCEPT Blood System helps in reducing the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. Cerus Corp has established collaborations with various blood centers and organizations worldwide to implement their solution and safeguard the blood supply. This California-based company continues to strive towards ensuring safer transfusions for patients globally.

The main competitors of Cerus Corp in the market include companies such as Grifols S.A., Baxter International Inc., and Terumo Corporation.

Cerus Corp is primarily active in the healthcare industry.

The business model of Cerus Corp revolves around developing and commercializing innovative systems for blood transfusion safety. Cerus Corp primarily focuses on the production of INTERCEPT Blood System, which is designed to minimize the risk of transfusion-transmitted infections. By providing pathogen inactivation technology, Cerus Corp ensures the safety and effectiveness of blood components for patients in need. With a commitment to improving global blood safety, Cerus Corp collaborates with blood centers, hospitals, and other healthcare institutions to implement their groundbreaking technology. Through its proactive approach, Cerus Corp aims to enhance the overall quality and access to safe blood transfusions worldwide.

Коефициентът на цена спрямо печалбата (КЦП) на Cerus е -15,15.

Коефициентът на цена към оборот (KUV) на Cerus е 1,99.

AlleAktien качественият резултат за Cerus е 4/10.

очаквана Cerus оборотът е 193,74 млн. USD.

очаквана Cerus печалба е -25,46 млн. USD.

Cerus Corporation is a biomedical company specializing in the development and commercialization of products for virus inactivation and blood transfusion safety, as well as devices for plasmapheresis. The company was founded in 1991 and is headquartered in Concord, California, USA.

Cerus разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Cerus в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Cerus е US1570851014.

WKN на Cerus е 905249.

Тикерът на Cerus е CERS.

През последните 12 месеца Cerus изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Cerus да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Cerus в момента е .

Cerus изплаща дивидент на тримесечие. Той се разпределя в месеците .

Cerus платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Cerus се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Cerus на 11.08.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 11.08.2024 г..

Последното дивидентно плащане беше извършено на 11.08.2024 г..

През година 2023 Cerus изплати 0 USD под формата на дивиденти.

Дивидентите от Cerus се изплащат в USD.